Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human hyaluronidase PH20 + mitomycin
- Development stage
- Unknown
- Lead developer
- Halozyme
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravesical
01
Overview
A **combination therapy** of recombinant human hyaluronidase PH20 (marketed as Chemophase), a recombinant enzyme that degrades hyaluronan in extracellular matrices, and **mitomycin** (mitomycin C), an anti-tumor antibiotic used as a chemotherapy agent. Recombinant human hyaluronidase PH20 improves the delivery and local penetration of mitomycin by breaking down hyaluronan barriers, potentially enhancing the efficacy of intravesically administered chemotherapy for **non-muscle-invasive (superficial) bladder cancer**. The combination is administered **intravesically (directly into the bladder)** after transurethral resection to target residual cancer cells, aiming to improve the anti-tumor activity and reduce recurrence rates. Development has been led by Halozyme Therapeutics, with Chemophase specifically developed for use with mitomycin in this indication[1][3][4].
- Brand names
- Chemophase
- Other names
- recombinant human hyaluronidase PH20 and mitomycinrHuPH20 + mitomycinChemophase + mitomycin C
02
Targets
DNA
Beyond the preview
Go deeper on recombinant human hyaluronidase PH20 + mitomycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human hyaluronidase PH20 + mitomycin.